Panbela Therapeutics (PBLA) 10-K 24 Mar 22 2021 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2021	Mar. 22, 2022	Jun. 29, 2021
Document Information [Line Items]
Entity Central Index Key	0001029125
Entity Registrant Name	Panbela Therapeutics, Inc.
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2021
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2021
Document Transition Report	false
Entity File Number	001-39468
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	87-0543922
Entity Address, Address Line One	712 Vista Blvd, #305
Entity Address, City or Town	Waconia
Entity Address, State or Province	MN
Entity Address, Postal Zip Code	55387
City Area Code	952
Local Phone Number	479-1196
Title of 12(b) Security	Common Stock, $0.001 par value
Trading Symbol	PBLA
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Small Business	true
Entity Filer Category	Non-accelerated Filer
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	false
Entity Shell Company	false
Entity Public Float			$ 33,799,047
Entity Common Stock, Shares Outstanding		13,449,117
Auditor Name	Cherry Bekaert
Auditor Location	Tampa, Florida
Auditor Firm ID	677

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 11,867,000	$ 9,022,000
Prepaid expenses and other current assets	91,000	412,000
Income tax receivable	321,000	323,000
Total current assets	12,279,000	9,757,000
Other noncurrent assets	593,000	56,000
Total assets	12,872,000	9,813,000
Current liabilities:
Accounts payable	640,000	554,000
Accrued expenses	2,020,000	811,000
Total current liabilities	2,660,000	1,365,000
Total liabilities	2,660,000	1,365,000
Stockholders' equity:
Preferred stock, $0.001 par value; 10,000,000 authorized; no shares issued or outstanding as of December 31, 2021 and December 31, 2020	0	0
Common stock, $0.001 par value; 100,000,000 authorized; 13,443,722 and 9,664,427 shares issued and outstanding, as of December 31, 2021 and December 31, 2020, respectively	13,000	10,000
Additional paid-in capital	66,227,000	54,848,000
Accumulated deficit	(56,161,000)	(46,026,000)
Accumulated comprehensive income (loss)	133,000	(384,000)
Total stockholders' equity	10,212,000	8,448,000
Total liabilities and stockholders' equity	$ 12,872,000	$ 9,813,000

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - $ / shares	Dec. 31, 2021	Dec. 31, 2020
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	13,443,722	9,664,427
Common stock, shares outstanding (in shares)	13,443,722	9,664,427

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Operating expenses:
General and administrative	$ 4,587	$ 3,249
Research and development	5,423	2,505
Operating loss	(10,010)	(5,754)
Other (expense) income:
Interest expense	(11)	(17)
Gain on debt forgiveness	0	103
Other (expense) income	(602)	605
Total other (expense) income	(613)	691
Loss before income tax benefit	(10,623)	(5,063)
Income tax benefit	488	295
Net loss	(10,135)	(4,768)
Foreign currency translation adjustment	517	(688)
Comprehensive loss	$ (9,618)	$ (5,456)
Basic and diluted net loss per share (in dollars per share)	$ (0.87)	$ (0.62)
Weighted average shares outstanding - basic and diluted (in shares)	11,709,035	7,732,882

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Private Placement [Member]Common Stock [Member]	Private Placement [Member]Additional Paid-in Capital [Member]	Private Placement [Member]Retained Earnings [Member]	Private Placement [Member]AOCI Attributable to Parent [Member]	Private Placement [Member]	Underwritten Public Offering [Member]Common Stock [Member]	Underwritten Public Offering [Member]Additional Paid-in Capital [Member]	Underwritten Public Offering [Member]Retained Earnings [Member]	Underwritten Public Offering [Member]AOCI Attributable to Parent [Member]	Underwritten Public Offering [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Balances (in shares) at Dec. 31, 2019											6,631,000
Balances at Dec. 31, 2019											$ 7	$ 42,331	$ (41,258)	$ 304	$ 1,384
Warrants issued											$ 0	228	0	0	228
Sale of common stock and warrants (in shares)	437,000					2,545,000
Sale of common stock and warrants	$ 0	$ 1,746	$ 0	$ 0	$ 1,746	$ 3	$ 9,218	$ 0	$ 0	$ 9,221
Exercise of warrants for cash (in shares)											43,000
Exercise of warrants for cash											$ 0	120	0	0	120
Exercise of warrants, cashless (in shares)											8,000
Exercise of warrants, cashless											$ 0	0	0	0	0
Stock-based compensation											0	1,205	0	0	1,205
Net loss											0	0	(4,768)	0	(4,768)
Foreign currency translation adjustment											$ 0	0		(688)	$ (688)
Exercise of options, cashless (in shares)															0
Balances (in shares) at Dec. 31, 2020											9,664,000
Balances at Dec. 31, 2020											$ 10	54,848	(46,026)	(384)	$ 8,448
Sale of common stock and warrants (in shares)						3,333,000
Sale of common stock and warrants						$ 3	$ 9,051	$ 0	$ 0	$ 9,054
Exercise of warrants for cash (in shares)											229,000				228,939
Exercise of warrants for cash											$ 0	1,041	0	0	$ 1,041
Exercise of warrants, cashless (in shares)											191,000				190,588
Exercise of warrants, cashless											$ 0	0	0	0	$ 0
Stock-based compensation											0	1,287	0	0	1,287
Net loss											0	0	(10,135)	0	(10,135)
Foreign currency translation adjustment											$ 0	0	0	517	517
Vesting of restricted stock (in shares)											22,000
Vesting of restricted stock											$ 0	0	0	0	$ 0
Exercise of options, cashless (in shares)											4,000				8,000
Exercise of options, cashless											$ 0	0	0	0	$ 0
Balances (in shares) at Dec. 31, 2021											13,443,000
Balances at Dec. 31, 2021											$ 13	$ 66,227	$ (56,161)	$ 133	$ 10,212

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities:
Net loss	$ (10,135,000)	$ (4,768,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	1,287,000	1,205,000
Forgiveness of Paycheck Protection Program loan	0	(103,000)
Changes in operating assets and liabilities:
Income tax receivable	51,000	(2,000)
Prepaid expenses and other current assets	247,000	67,000
Accounts payable	631,000	(747,000)
Accrued liabilities	1,215,000	494,000
Net cash used in operating activities	(6,704,000)	(3,854,000)
Cash flows from investing activities:
Deposits held by Contract Research Organizations	(540,000)	0
Net cash used in investing activities	(540,000)	0
Cash flows from financing activities:
Proceeds from sale of common stock and warrants net of offering costs of $2		1,746,000
Proceeds from exercise of warrants	1,041,000	120,000
Proceeds from Paycheck Protection Program loan	0	103,000
Repayments of demand note	0	(743,000)
Repayments of term debt	0	(117,000)
Net cash provided by financing activities	10,095,000	10,444,000
Effect of exchange rate changes on cash	(6,000)	(17,000)
Net change in cash	2,845,000	6,573,000
Cash and cash equivalents at beginning of period	9,022,000	2,449,000
Cash and cash equivalents at end of period	11,867,000	9,022,000
Supplemental disclosure of cash flow information:
Cash paid during period for interest	12,000	8,000
Supplemental disclosure of non-cash transactions:
Warrants issued for future services	0	228,000
Warrants issued to underwriter	0	353,000
Amortization of warrants as offering costs	0	114,000
Underwritten Public Offering [Member]
Cash flows from financing activities:
Proceeds from public offering of common stock and warrants net of underwriters discount and offering costs of $1,165		$ 9,335,000
Proceeds from public offering of common stock net of underwriters discount and offering costs of $946	$ 9,054,000

Consolidated Statements of Ca_2

Consolidated Statements of Cash Flows (Parentheticals) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Proceeds from issuance of common stock and warrants, issuance costs	$ 946	$ 1,165
Private Placement [Member]
Proceeds from issuance of common stock and warrants, issuance costs		$ 2

Note 1 - Business

Note 1 - Business	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. Business Panbela Therapeutics, Inc., and its wholly owned subsidiary Panbela Therapeutics Pty Ltd, (collectively “we,” “us,” “our,” and the “Company”) exist for the primary purpose of advancing the commercial development of a proprietary polyamine analogue for pancreatic cancer. We have exclusively licensed the worldwide rights to this compound, which was designated as SBP- 101, September 21, 2011. May 24, 2013

Note 2 - Risks and Uncertaintie

Note 2 - Risks and Uncertainties	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Nature of Operations [Text Block]	2. Risks and Uncertainties The Company operates in a highly regulated and competitive environment. The development, manufacturing and marketing of pharmaceutical products require approval from, and are subject to ongoing oversight by, the Food and Drug Administration (“FDA”) in the United States, the Therapeutic Goods Administration (“TGA”) in Australia, the European Medicines Agency (“EMA”) in the European Union, and comparable agencies in other countries. Obtaining approval for a new pharmaceutical product is never certain, may We have incurred losses of $56.2 million since our inception in 2011. December 31, 2021, 101. December 31, 2021, The accompanying Consolidated Financial Statements have been prepared assuming that we will continue as a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business and do not 101, December 2021 21 19” 19, 2020 first 2021 second 2021 2021 first 2022. 19 19 2020 19. No 19 December 2020. 2021, 19. no January 2022, not 19. no

Note 3 - Liquidity and Manageme

Note 3 - Liquidity and Management Plans	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Substantial Doubt about Going Concern [Text Block]	3. Liquidity and Management Plans We will need to seek additional sources of funds to support our current business plans. We may no not If we are unable to obtain additional financing when needed, we would need to scale back our operations taking actions that may 101 third 101 On July 2, 2021, first 2021, On September 1, 2020, June 30, 2020, It is expected that cash will last into the fourth 2022. Our future success is dependent upon our ability to obtain additional financing, the success of our development efforts, our ability to demonstrate clinical progress for our SBP- 101 101 not not no

Note 4 - Summary of Significant

Note 4 - Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Significant Accounting Policies [Text Block]	4. Summary of Significant Accounting Policies Basis of presentation We have prepared the accompanying Consolidated Financial Statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Our fiscal year ends on December 31. Principles of consolidation The accompanying Consolidated Financial Statements include the assets, liabilities and expenses of Panbela Therapeutics, Inc. and our wholly owned subsidiary. All significant intercompany transactions and balances have been eliminated in consolidation. Use of estimates The preparation of Consolidated Financial Statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Consolidated Financial Statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates. Concentration of credit risk Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash. Cash is deposited in demand accounts at commercial banks. At times, such deposits may December 31, 2021, not Cash and cash equivalents Cash equivalents include short-term, highly liquid investments with maturities of three Other non-current assets Other noncurrent assets are comprised primarily of long-term deposits with contract research organizations (“CROs”). These amounts are recognized as operating expenses or research and development expense as the trial is completed. Research and development costs Research and development costs include expenses incurred in the conduct of our Phase I and Phase II/III human clinical trials, for third 101 101 We charge research and development costs, including clinical trial costs, to expense when incurred. Our human clinical trials are performed at clinical trial sites and are administered jointly by us with assistance from CROs. Costs of setting up clinical trial sites are accrued upon execution of the study agreement. Expenses related to the performance of clinical trials generally are accrued based on contracted amounts and the achievement of agreed upon milestones, such as site openings, patient enrollment, patient follow-up, etc. We monitor levels of performance under each significant contract, including the extent of patient enrollment and other activities through communications with the clinical trial sites and CROs, and adjust the estimates, if required, on a quarterly basis so that clinical expenses reflect the actual effort expended at each clinical trial site and by each CRO. We expense costs associated with obtaining licenses for patented technologies when it is determined there is no Clinical Trial Accruals Costs for preclinical studies and clinical trial activities are recognized based on an evaluation of the vendors’ progress towards completion of specific tasks, using data such as clinical site activations, patient enrollment or information provided to the Company by its vendors regarding their actual costs incurred. Payments for these activities are based on the terms of individual contracts and payment timing may Stock-based compensation In accounting for stock-based incentive awards, we measure and recognize the cost of employee and non-employee services received in exchange for awards of equity instruments based on the grant date fair value of those awards. Compensation cost is recognized ratably using the straight-line attribution method over the vesting period, which is considered to be the requisite service period. We record forfeitures in the periods in which they occur. The compensation expense for performance-based stock option awards is recognized when “performance” has occurred or is probable of occurring. The fair value of stock-based awards is estimated at the date of grant using the Black-Scholes option pricing model. The determination of the fair value of stock-based awards is affected by our stock price, as well as assumptions regarding a number of complex and subjective variables. Risk free interest rates are based upon U.S. Treasury rates appropriate for the expected term of each award. Expected volatility rates are based primarily on the volatility rates of a set of guideline companies, which consist of public and recently public biotechnology companies. The assumed dividend yield is zero, as we do not The fair value of restricted stock units is calculated as the fair value of the underlying common stock as of the date of grant. Income taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the Consolidated Financial Statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted rates, for each of the jurisdictions in which the Company operates, expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. Valuation allowances are established when necessary to reduce deferred tax assets to the amount that is more likely than not December 31, 2021 2020. Foreign currency translation The functional currency of Panbela Therapeutics Pty Ltd is the Australian Dollar (“AUD”). Accordingly, assets and liabilities, and equity transactions of Panbela Therapeutics Pty Ltd are translated into U.S. dollars at period-end exchange rates. Expenses are translated at the average exchange rate in effect for the period. The resulting translation gains and losses are recorded as a component of accumulated comprehensive gain (loss) in the Consolidated Statements of Operations and Comprehensive Loss. During the years ended December 31, 2021 2020, Net loss per share We compute net loss per share by dividing our net loss (the numerator) by the weighted-average number of common shares outstanding (the denominator) during the period. Shares issued during the period and shares reacquired during the period, if any, are weighted for the portion of the period that they were outstanding. The computation of diluted earnings per share, or EPS, is similar to the computation of basic EPS except that the denominator is increased to include the number of additional common shares that would have been outstanding if the dilutive potential common shares had been issued. Our diluted EPS is the same as basic EPS due to common equivalent shares being excluded from the calculation, as their effect is anti-dilutive. The following outstanding potential common shares were not not December 31, 2021 2020 Employee and non-employee stock options 2,463,636 2,137,499 Restricted stock units 10,790 11,500 Common stock issuable under common stock purchase warrants 5,109,501 6,556,468 7,583,927 8,705,467 Recently Adopted Accounting Pronouncements In August 2020, No. 2020 06, 470 20 815 40 December 15, 2021, no December 15, 2020. not

Note 5 - Accrued Expenses

Note 5 - Accrued Expenses	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Accrued Liabilities [Text Block]	5. Accrued Expenses Accrued expenses consisted of the following (in thousands): December 31, 2021 2020 Clinical trial and related expenses $ 992 $ 186 Incentive compensation 434 497 Professional services 235 98 Other 359 30 Total accrued liabilities $ 2,020 $ 811

Note 6 - Indebtedness

Note 6 - Indebtedness	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Debt Disclosure [Text Block]	6. Indebtedness PPP loan On May 1, 2020, March 27, 2020. 100% may December 30, 2020 2020

Note 7 - Commitments and Contin

Note 7 - Commitments and Contingencies	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	7. Commitments and Contingencies License agreement On December 22, 2011, first December 12, 2016 ( October 3, 2019 ( 1 ten first 2 The amended license agreement remains subject to customary and usual termination provisions. The Company must also pay an annual license maintenance fee of $10,000. Consulting agreement In July 2021, December 31, 2021.

Note 8 - Stockholders' Equity

Note 8 - Stockholders' Equity	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	8. Stockholders Equity Public offering of common stock On July 2, 2021, 3. Public offering of common stock and warrants On September 1, 2020, five 1. August 28, 2020. December 31, 2021, 3, Underwriter warrant to purchase common stock On September 1, 2020, five Exercise of Warrants to purchase common stock During the year ended December 31, 2021, 1. December 31, 2021. December 31, 2021. During the quarter ended December 31, 2020, 1. On September 1, 2020, Private placements of common stock and warrants On closings occurring in May June 2020, five 3, Warrants to purchase common stock issued for future services On February 21, 2020, five one September 1, 2020 2021. Shares reserved Shares of common stock reserved for future issuance were as follows as of December 31, 2021: Stock options outstanding 2,463,636 Restricted stock units outstanding 10,790 Shares available for grant under equity incentive plan 1,345,863 Common shares issuable under outstanding common stock purchase warrants 5,109,501 8,929,790

Note 9 - Stock-based Compensati

Note 9 - Stock-based Compensation	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	9. Stock-Based Compensation 2016 The. 2016 April 9, 2020 ( “2016 2016 2016 not 2016 ten 2016 December 31, 2021, 2016 2011 Prior to approval of the 2016 2011 “2011 2016 2011 2011 2011 ten zero two December 31, 2021, 2011 We recognize stock-based compensation based on the fair value of each award as estimated using the Black-Scholes option valuation model. Ultimately, the actual expense recognized over the vesting period will only be for those shares that actually vest. A summary of option activity is as follows: Shares Underlying Options Weighted Average Exercise Price Per Share Aggregate Intrinsic Value Balance at January 1, 2020 1,744,811 $ 6.53 $ 1,047,197 Granted 425,648 7.48 Exercised - - Cancelled (32,360 ) 2.42 Forfeitures (600 ) 15.10 Balance at December 31, 2020 2,137,499 $ 6.77 $ 388,461 Granted 554,065 3.86 Exercised (8,000 ) 0.88 Cancelled - - Forfeitures (219,928 ) 10.27 Balance at December 31, 2021 2,463,636 $ 5.83 $ 8,821 Stock-based compensation expense for each of the periods presented is as follows (in thousands): Year ended December 31, 2021 2020 General and administrative $ 1,083 $ 1,068 Research and development 204 137 Total stock based compensation $ 1,287 $ 1,205 A summary of the status of our unvested shares during the two December 31, 2021 Shares Under Option Weighted Average Grant Date Fair Value Unvested at January 1, 2020 397,875 $ 2.03 Granted 425,648 5.39 Vested (322,437 ) 3.14 Forfeitures - - Unvested at December 31, 2020 501,086 $ 4.17 Granted 554,065 2.97 Vested (286,157 ) 3.61 Forfeitures (50,000 ) 2.98 Unvested at December 31, 2021 718,994 $ 3.39 Information about stock options outstanding, vested and expected to vest as of December 31, 2021, Outstanding, Vested and Expected to Vest Options Vested and Exercisable Per Share Exercise Price Shares Weighted Average Remaining Contractual Life (Years) Weighted Average Exercise Price Options Exercisable Weighted Average Remaining Contractual Life (Years) $1.10 14,000 1.45 $ 1.100 14,000 1.45 $2.26 - $2.50 79,225 7.62 $ 2.310 22,000 2.44 $2.95 - $4.17 1,207,940 7.45 $ 3.410 729,695 6.05 $4.50 - $8.10 687,100 6.69 $ 6.134 609,600 6.47 $9.99 - $10.10 266,048 7.93 $ 9.994 160,024 7.53 $15.10 209,323 4.57 $ 15.100 209,323 4.57 Totals 2,463,636 7.29 $ 5.825 1,744,642 6.23 As of December 31, 2021, not The assumptions used in calculating the fair value under the Black-Scholes option valuation model are set forth in the following table for options issued by the Company for the years ended December 31, 2021 2020: 2021 2020 Common stock fair value $2.26 - 4.17 $4.82 - 9.99 Risk-free interest rate 0.79 - 1.08% 0.29 - 0.39% Expected dividend yield 0 0 Expected Option life(years) 5.30 - 5.75 5.00 - 5.75 Expected stock price volatility 90% 90% Nonemployee stock-based compensation We account for stock options granted to nonemployees in accordance with Accounting Standards Update (“ASU”) 2019 07, 718 2021 2020, Restricted stock units The number and weighted average grant date fair value of restricted non vested common stock for the most recent completed fiscal years is as follows: Number of Restricted Shares Weighted Average Grant Date Fair Value Restricted nonvested at January 1, 2020 - $ - Granted in 2020 11,500 3.45 Vested in 2020 - - Restricted nonvested at December 31, 2020 11,500 3.45 Granted in 2021 21,580 4.17 Vested in 2021 (22,290 ) 3.80 Restricted nonvested at December 31, 2021 10,790 $ 4.17 As of December 31, 2021, not Stock compensation expense includes expense related to restricted stock units of approximately $106,000 in 2021.

Note 10 - Income Taxes

Note 10 - Income Taxes	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Income Tax Disclosure [Text Block]	10. Income Taxes We have incurred net operating losses since inception. We have not On December 31, 2021 2020, Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes as well as operating losses and tax credit carryforwards. The significant components of our deferred tax assets and liabilities are as follows (in thousands): December 31, Deferred tax assets (liabilities) 2021 2020 Net operating loss carryforwards $ 9,986 $ 7,660 Research credit carryforwards 235 235 Stock-based compensation 1,734 1,498 Other 66 70 Deferred tax assets 12,021 9,463 Valuation allowance (12,021 ) (9,463 ) Net deferred tax asset $ - $ - Realization of the future tax benefits is dependent on our ability to generate sufficient taxable income within the carry-forward period. Because of our history of operating losses, management believes that the deferred tax assets arising from the above-mentioned future tax benefits are currently not A reconciliation of the statutory tax rates and the effective tax rates is as follows: Year Ended December 31, 2021 2020 Statutory rate 21.0 % 21.0 % Permanent differences 2.1 1.7 Change in effective tax rate (0.4 ) - Valuation allowance (24.3 ) (26.5 ) Foreign research incentives 3.1 5.4 Other 1.6 3.8 Effective rate 3.1 % 5.4 % Net operating losses and tax credit carryforwards as of December 31, 2021, (In Thousands) Amount Expiration Years Net operating losses--federal 12,958 Expires beginning 2031 2018 to 2021 net operating losses -- federal 12,068 Never expires Tax credits--federal 235 Beginning 2041 Utilization of the net operating loss carryforwards and credits may not 382 The Company is subject to taxation in the United States and Australia. Tax returns for the year ended December 31, 2017 December 31, 2015

Note 11 - Subsequent Events

Note 11 - Subsequent Events	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Subsequent Events [Text Block]	11. Subsequent Events On February 21, 2022, first Under the terms of the agreement and plan of merger, the holders of CPP’s outstanding capital stock immediately prior to the merger will receive shares of common stock of Panbela upon closing of the Mergers. On a pro forma and fully diluted basis, holders of Panbela common stock are expected to own approximately 59% of the post-merger holding company and holders of CPP securities, including converted indebtedness, are expected to beneficially own approximately 41% of post-merger holding company. CPP stockholders will be eligible to receive contingent payments totaling a maximum of $60 million from milestone and royalty payments associated with the potential approval and commercialization of the lead asset.

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of presentation We have prepared the accompanying Consolidated Financial Statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Our fiscal year ends on December 31.
Consolidation, Policy [Policy Text Block]	Principles of consolidation The accompanying Consolidated Financial Statements include the assets, liabilities and expenses of Panbela Therapeutics, Inc. and our wholly owned subsidiary. All significant intercompany transactions and balances have been eliminated in consolidation.
Use of Estimates, Policy [Policy Text Block]	Use of estimates The preparation of Consolidated Financial Statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Consolidated Financial Statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of credit risk Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash. Cash is deposited in demand accounts at commercial banks. At times, such deposits may December 31, 2021, not
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and cash equivalents Cash equivalents include short-term, highly liquid investments with maturities of three
Other Non-current Assets [Policy Text Block]	Other non-current assets Other noncurrent assets are comprised primarily of long-term deposits with contract research organizations (“CROs”). These amounts are recognized as operating expenses or research and development expense as the trial is completed.
Research and Development Expense, Policy [Policy Text Block]	Research and development costs Research and development costs include expenses incurred in the conduct of our Phase I and Phase II/III human clinical trials, for third 101 101 We charge research and development costs, including clinical trial costs, to expense when incurred. Our human clinical trials are performed at clinical trial sites and are administered jointly by us with assistance from CROs. Costs of setting up clinical trial sites are accrued upon execution of the study agreement. Expenses related to the performance of clinical trials generally are accrued based on contracted amounts and the achievement of agreed upon milestones, such as site openings, patient enrollment, patient follow-up, etc. We monitor levels of performance under each significant contract, including the extent of patient enrollment and other activities through communications with the clinical trial sites and CROs, and adjust the estimates, if required, on a quarterly basis so that clinical expenses reflect the actual effort expended at each clinical trial site and by each CRO. We expense costs associated with obtaining licenses for patented technologies when it is determined there is no
Clinical Trial Accruals [Policy Text Block]	Clinical Trial Accruals Costs for preclinical studies and clinical trial activities are recognized based on an evaluation of the vendors’ progress towards completion of specific tasks, using data such as clinical site activations, patient enrollment or information provided to the Company by its vendors regarding their actual costs incurred. Payments for these activities are based on the terms of individual contracts and payment timing may
Share-based Payment Arrangement [Policy Text Block]	Stock-based compensation In accounting for stock-based incentive awards, we measure and recognize the cost of employee and non-employee services received in exchange for awards of equity instruments based on the grant date fair value of those awards. Compensation cost is recognized ratably using the straight-line attribution method over the vesting period, which is considered to be the requisite service period. We record forfeitures in the periods in which they occur. The compensation expense for performance-based stock option awards is recognized when “performance” has occurred or is probable of occurring. The fair value of stock-based awards is estimated at the date of grant using the Black-Scholes option pricing model. The determination of the fair value of stock-based awards is affected by our stock price, as well as assumptions regarding a number of complex and subjective variables. Risk free interest rates are based upon U.S. Treasury rates appropriate for the expected term of each award. Expected volatility rates are based primarily on the volatility rates of a set of guideline companies, which consist of public and recently public biotechnology companies. The assumed dividend yield is zero, as we do not The fair value of restricted stock units is calculated as the fair value of the underlying common stock as of the date of grant.
Income Tax, Policy [Policy Text Block]	Income taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the Consolidated Financial Statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted rates, for each of the jurisdictions in which the Company operates, expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. Valuation allowances are established when necessary to reduce deferred tax assets to the amount that is more likely than not December 31, 2021 2020.
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign currency translation The functional currency of Panbela Therapeutics Pty Ltd is the Australian Dollar (“AUD”). Accordingly, assets and liabilities, and equity transactions of Panbela Therapeutics Pty Ltd are translated into U.S. dollars at period-end exchange rates. Expenses are translated at the average exchange rate in effect for the period. The resulting translation gains and losses are recorded as a component of accumulated comprehensive gain (loss) in the Consolidated Statements of Operations and Comprehensive Loss. During the years ended December 31, 2021 2020,
Earnings Per Share, Policy [Policy Text Block]	Net loss per share We compute net loss per share by dividing our net loss (the numerator) by the weighted-average number of common shares outstanding (the denominator) during the period. Shares issued during the period and shares reacquired during the period, if any, are weighted for the portion of the period that they were outstanding. The computation of diluted earnings per share, or EPS, is similar to the computation of basic EPS except that the denominator is increased to include the number of additional common shares that would have been outstanding if the dilutive potential common shares had been issued. Our diluted EPS is the same as basic EPS due to common equivalent shares being excluded from the calculation, as their effect is anti-dilutive. The following outstanding potential common shares were not not December 31, 2021 2020 Employee and non-employee stock options 2,463,636 2,137,499 Restricted stock units 10,790 11,500 Common stock issuable under common stock purchase warrants 5,109,501 6,556,468 7,583,927 8,705,467
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Adopted Accounting Pronouncements In August 2020, No. 2020 06, 470 20 815 40 December 15, 2021, no December 15, 2020. not

Note 4 - Summary of Significa_2

Note 4 - Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	December 31, 2021 2020 Employee and non-employee stock options 2,463,636 2,137,499 Restricted stock units 10,790 11,500 Common stock issuable under common stock purchase warrants 5,109,501 6,556,468 7,583,927 8,705,467

Note 5 - Accrued Expenses (Tabl

Note 5 - Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	December 31, 2021 2020 Clinical trial and related expenses $ 992 $ 186 Incentive compensation 434 497 Professional services 235 98 Other 359 30 Total accrued liabilities $ 2,020 $ 811

Note 8 - Stockholders' Equity (

Note 8 - Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Schedule of Common Stock Reserved for Future Issuance [Table Text Block]	Stock options outstanding 2,463,636 Restricted stock units outstanding 10,790 Shares available for grant under equity incentive plan 1,345,863 Common shares issuable under outstanding common stock purchase warrants 5,109,501 8,929,790

Note 9 - Stock-based Compensa_2

Note 9 - Stock-based Compensation (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Share-based Payment Arrangement, Option, Activity [Table Text Block]	Shares Underlying Options Weighted Average Exercise Price Per Share Aggregate Intrinsic Value Balance at January 1, 2020 1,744,811 $ 6.53 $ 1,047,197 Granted 425,648 7.48 Exercised - - Cancelled (32,360 ) 2.42 Forfeitures (600 ) 15.10 Balance at December 31, 2020 2,137,499 $ 6.77 $ 388,461 Granted 554,065 3.86 Exercised (8,000 ) 0.88 Cancelled - - Forfeitures (219,928 ) 10.27 Balance at December 31, 2021 2,463,636 $ 5.83 $ 8,821
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Year ended December 31, 2021 2020 General and administrative $ 1,083 $ 1,068 Research and development 204 137 Total stock based compensation $ 1,287 $ 1,205
Schedule of Nonvested Share Activity [Table Text Block]	Shares Under Option Weighted Average Grant Date Fair Value Unvested at January 1, 2020 397,875 $ 2.03 Granted 425,648 5.39 Vested (322,437 ) 3.14 Forfeitures - - Unvested at December 31, 2020 501,086 $ 4.17 Granted 554,065 2.97 Vested (286,157 ) 3.61 Forfeitures (50,000 ) 2.98 Unvested at December 31, 2021 718,994 $ 3.39
Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block]	Outstanding, Vested and Expected to Vest Options Vested and Exercisable Per Share Exercise Price Shares Weighted Average Remaining Contractual Life (Years) Weighted Average Exercise Price Options Exercisable Weighted Average Remaining Contractual Life (Years) $1.10 14,000 1.45 $ 1.100 14,000 1.45 $2.26 - $2.50 79,225 7.62 $ 2.310 22,000 2.44 $2.95 - $4.17 1,207,940 7.45 $ 3.410 729,695 6.05 $4.50 - $8.10 687,100 6.69 $ 6.134 609,600 6.47 $9.99 - $10.10 266,048 7.93 $ 9.994 160,024 7.53 $15.10 209,323 4.57 $ 15.100 209,323 4.57 Totals 2,463,636 7.29 $ 5.825 1,744,642 6.23
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	2021 2020 Common stock fair value $2.26 - 4.17 $4.82 - 9.99 Risk-free interest rate 0.79 - 1.08% 0.29 - 0.39% Expected dividend yield 0 0 Expected Option life(years) 5.30 - 5.75 5.00 - 5.75 Expected stock price volatility 90% 90%
Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]	Number of Restricted Shares Weighted Average Grant Date Fair Value Restricted nonvested at January 1, 2020 - $ - Granted in 2020 11,500 3.45 Vested in 2020 - - Restricted nonvested at December 31, 2020 11,500 3.45 Granted in 2021 21,580 4.17 Vested in 2021 (22,290 ) 3.80 Restricted nonvested at December 31, 2021 10,790 $ 4.17

Note 10 - Income Taxes (Tables)

Note 10 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	December 31, Deferred tax assets (liabilities) 2021 2020 Net operating loss carryforwards $ 9,986 $ 7,660 Research credit carryforwards 235 235 Stock-based compensation 1,734 1,498 Other 66 70 Deferred tax assets 12,021 9,463 Valuation allowance (12,021 ) (9,463 ) Net deferred tax asset $ - $ -
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	Year Ended December 31, 2021 2020 Statutory rate 21.0 % 21.0 % Permanent differences 2.1 1.7 Change in effective tax rate (0.4 ) - Valuation allowance (24.3 ) (26.5 ) Foreign research incentives 3.1 5.4 Other 1.6 3.8 Effective rate 3.1 % 5.4 %
Summary of Operating Loss and Tax Credit Carryforwards [Table Text Block]	(In Thousands) Amount Expiration Years Net operating losses--federal 12,958 Expires beginning 2031 2018 to 2021 net operating losses -- federal 12,068 Never expires Tax credits--federal 235 Beginning 2041

Note 2 - Risks and Uncertaint_2

Note 2 - Risks and Uncertainties (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Retained Earnings (Accumulated Deficit), Ending Balance	$ (56,161)	$ (46,026)
Net Income (Loss) Attributable to Parent, Total	(10,135)	(4,768)
Net Cash Provided by (Used in) Operating Activities, Total	(6,704)	(3,854)
Cash and Cash Equivalents, at Carrying Value, Ending Balance	11,867	9,022
Working Capital	9,600
Stockholders' Equity Attributable to Parent, Ending Balance	$ 10,212	$ 8,448	$ 1,384

Note 3 - Liquidity and Manage_2

Note 3 - Liquidity and Management Plans (Details Textual) - USD ($)	Jul. 02, 2021	Sep. 01, 2020	Mar. 23, 2021	Jun. 30, 2020	Dec. 31, 2020	Jun. 30, 2020	Dec. 31, 2021	Dec. 31, 2020
Proceeds from Warrant Exercises			$ 1,000,000		$ 68,000		$ 1,041,000	$ 120,000
Stock Issued During Period, Shares, Exercise of Warrants for Cash (in shares)			228,939				228,939
Proceeds from Issuance of Private Placement								1,746,000
Underwritten Public Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)	3,333,334	2,545,454
Shares Issued, Price Per Share (in dollars per share)	$ 3
Proceeds from Issuance of Common Stock, Net	$ 9,100,000						$ 9,054,000
Stock Issued During Period, Shares, Exercise of Warrants for Cash (in shares)		27,500
Proceeds from Issuance of Common Stock, Net		$ 9,300,000						$ 9,335,000
Private Placement [Member]
Stock Issued During Period, Shares, New Issues (in shares)				437,000
Proceeds from Issuance of Private Placement				$ 1,700,000		$ 1,700,000

Note 4 - Summary of Significa_3

Note 4 - Summary of Significant Accounting Policies (Details Textual) $ in Millions	Dec. 31, 2021USD ($)
Cash, Uninsured Amount	$ 11.6

Note 4 - Summary of Significa_4

Note 4 - Summary of Significant Accounting Policies - Anti-dilutive Securities (Details) - shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Anti-dilutive securities (in shares)	7,583,927	8,705,467
Share-based Payment Arrangement [Member]
Anti-dilutive securities (in shares)	2,463,636	2,137,499
Restricted Stock Units (RSUs) [Member]
Anti-dilutive securities (in shares)	10,790	11,500
Warrant [Member]
Anti-dilutive securities (in shares)	5,109,501	6,556,468

Note 5 - Accrued Expenses - Acc

Note 5 - Accrued Expenses - Accrued Expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Clinical trial and related expenses	$ 992	$ 186
Incentive compensation	434	497
Professional services	235	98
Other	359	30
Accrued liabilities	$ 2,020	$ 811

Note 6 - Indebtedness (Details

Note 6 - Indebtedness (Details Textual)	May 01, 2020USD ($)
Proceeds from Paycheck Protection Program Under CARES Act	$ 103,000

Note 7 - Commitments and Cont_2

Note 7 - Commitments and Contingencies (Details Textual) - USD ($)	Dec. 22, 2011	Dec. 31, 2021
Member of Board of Directors [Member] | Consulting Services [Member]
Related Party Transaction, Purchases from Related Party		$ 54,600
Licensing Agreement with University of Florida Research Foundation [Member]
Royalty Term (Year)	10 years
Annual License Maintenance Fee	$ 10,000
Licensing Agreement with University of Florida Research Foundation [Member] | Minimum [Member]
Royalty Fee Percentage of Net Sales	2.50%
Licensing Agreement with University of Florida Research Foundation [Member] | Maximum [Member]
Royalty Fee Percentage of Net Sales	5.00%

Note 8 - Stockholders' Equity_2

Note 8 - Stockholders' Equity (Details Textual) - USD ($)	Jul. 02, 2021	Sep. 01, 2020	Mar. 23, 2021	Jun. 30, 2020	Dec. 31, 2020	Jun. 30, 2020	Dec. 31, 2021	Dec. 31, 2020	Feb. 21, 2020
Stock Issued During Period, Shares, Exercise of Warrants for Cash (in shares)			228,939				228,939
Proceeds from Warrant Exercises			$ 1,000,000		$ 68,000		$ 1,041,000	$ 120,000
Class of Warrant or Right, Exercised During Period (in shares)							536,140
Stock Issued During Period, Shares, Cashless Exercise of Warrants (in shares)							190,588
Stock Issued During Period, Shares, Warrants Exercised (in shares)					15,000
Stock Issued During Period, Value, Exercise of Warrants for Cash							$ 1,041,000	120,000
Proceeds from Issuance of Private Placement								1,746,000
Underwritten Public Offering Warrant [Member]
Warrants and Rights Outstanding, Term (Year)		5 years
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 4.54
Underwritten Public Offering [Member]
Class of Warrant or Right, Outstanding (in shares)							2,306,516
Underwritten Warrants [Member]
Warrants and Rights Outstanding, Term (Year)		5 years
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 4.537
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		127,273
Warrants and Rights Outstanding		$ 353,000
Class of Warrant or Right, Exercised During Period, Exercise Price (in dollars per share)		$ 1.875			$ 4.54
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)		15,000
Exercise of Warrants To Purchase Common Stock [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)							$ 4.54
Class of Warrant or Right, Exercised During Period (in shares)							223,939
Warrants With Exercise Price of $5.00 [Member]
Class of Warrants or Rights, Cancelled During the Period (in shares)							573,339
Class of Warrant or Right, Cancelled During Period, Exercise Price (in dollars per share)							$ 5
Warrants With Exercise Price of $15.00 [Member]
Class of Warrants or Rights, Cancelled During the Period (in shares)							108,550
Class of Warrant or Right, Cancelled During Period, Exercise Price (in dollars per share)							$ 15
Warrants in Connection with the Private Placement [Member]
Warrants and Rights Outstanding, Term (Year)				5 years		5 years
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)				$ 6		$ 6
Warrants Issued for Future Services [Member]
Warrants and Rights Outstanding, Term (Year)									5 years
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)									$ 6.49
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)									75,000
Warrants and Rights Outstanding									$ 228,000
Underwritten Public Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)	3,333,334	2,545,454
Shares Issued, Price Per Share (in dollars per share)	$ 3
Proceeds from Issuance of Common Stock	$ 10,000,000
Proceeds from Issuance of Common Stock, Net	$ 9,100,000						$ 9,054,000
Proceeds from Issuance or Sale of Equity, Total		$ 10,500,000
Proceeds from Issuance of Common Stock, Net		$ 9,300,000						$ 9,335,000
Stock Issued During Period, Shares, Exercise of Warrants for Cash (in shares)		27,500
Stock Issued During Period, Shares, Warrants Exercised (in shares)		35,665
Stock Issued During Period, Value, Exercise of Warrants for Cash		$ 52,000
Stock Issued During Period, Shares, Exercise of Warrants on Cashless Basis (in shares)		8,165
Warrants Issued, Cost Capitalized, Against Proceeds Received in Offering		$ 114,000
Underwritten Public Offering [Member] | Directors and Officers [Member]
Proceeds from Issuance or Sale of Equity, Total		$ 81,000
Private Placement [Member]
Stock Issued During Period, Shares, New Issues (in shares)				437,000
Proceeds from Issuance of Private Placement				$ 1,700,000		$ 1,700,000
Private Placement [Member] | Directors and Officers [Member]
Proceeds from Issuance of Private Placement				$ 50,000

Note 8 - Stockholders' Equity -

Note 8 - Stockholders' Equity - Common Stock Reserved for Future Issuance (Details)	Dec. 31, 2021shares
Common Stock, Capital Shares Reserved for Future Issuance (in shares)	8,929,790
Warrant [Member]
Common Stock, Capital Shares Reserved for Future Issuance (in shares)	5,109,501
Share-based Payment Arrangement, Option [Member]
Common Stock, Capital Shares Reserved for Future Issuance (in shares)	2,463,636
Restricted Stock Units (RSUs) [Member]
Common Stock, Capital Shares Reserved for Future Issuance (in shares)	10,790
Shares Available for Grant Under Equity Incentive Plan [Member]
Common Stock, Capital Shares Reserved for Future Issuance (in shares)	1,345,863

Note 9 - Stock-based Compensa_3

Note 9 - Stock-based Compensation (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Common Stock, Capital Shares Reserved for Future Issuance (in shares)	8,929,790
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance (in shares)	10,790
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)	2,463,636	2,137,499	1,744,811
Share-based Payment Arrangement, Expense	$ 1,287,000	$ 1,205,000
Restricted Stock Units (RSUs) [Member]
Common Stock, Capital Shares Reserved for Future Issuance (in shares)	10,790
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance (in shares)		11,500	0
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total	$ 17,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)	4 months 24 days
Share-based Payment Arrangement, Expense	$ 106,000
Share-based Payment Arrangement, Option [Member]
Common Stock, Capital Shares Reserved for Future Issuance (in shares)	2,463,636
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total	$ 1,700,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)	2 years 2 months 12 days
Non-Employee Stock Option [Member]
Share-based Payment Arrangement, Expense	$ 222,000	$ 261,000
Panbela Therapeutics, Inc. 2016 Omnibus Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)	10 years
Common Stock, Capital Shares Reserved for Future Issuance (in shares)	3,618,579
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)	2,239,636
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)	1,345,863
Panbela Therapeutics, Inc. 2016 Omnibus Incentive Plan [Member] | Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance (in shares)	10,790
Panbela Therapeutics, Inc. 2011 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)	10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)	224,000
Panbela Therapeutics, Inc. 2011 Stock Option Plan [Member] | Share-based Payment Arrangement, Option [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)	0 years
Panbela Therapeutics, Inc. 2011 Stock Option Plan [Member] | Share-based Payment Arrangement, Option [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)	2 years

Note 9 - Stock-based Compensa_4

Note 9 - Stock-based Compensation - Summary of Option Activity (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Balance, shares available for grant (in shares)	2,137,499	1,744,811
Balance, weighted average exercise price per share (in dollars per share)	$ 6.77	$ 6.53
Aggregate intrinsic value	$ 8,821	$ 388,461	$ 1,047,197
Granted, shares available for grant (in shares)	554,065	425,648
Granted, weighted average exercise price per share (in dollars per share)	$ 3.86	$ 7.48
Excercised, shares available for grant (in shares)	(8,000)	0
Cancelled, shares available for grant (in shares)	0	(32,360)
Cancelled, weighted average exercise price per share (in dollars per share)	$ 0.88	$ 2.42
Forfeitures , shares available for grant (in shares)	(219,928)	(600)
Forfeitures, weighted average exercise price per share (in dollars per share)	$ 10.27	$ 15.10
Balance, shares available for grant (in shares)	2,463,636	2,137,499
Balance, weighted average exercise price per share (in dollars per share)	$ 5.83	$ 6.77

Note 9 - Stock-based Compensa_5

Note 9 - Stock-based Compensation - Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Share-based compensation expense	$ 1,287	$ 1,205
General and Administrative Expense [Member]
Share-based compensation expense	1,083	1,068
Research and Development Expense [Member]
Share-based compensation expense	$ 204	$ 137

Note 9 - Stock-based Compensa_6

Note 9 - Stock-based Compensation - Nonvested Share Activity (Details) - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Unvested, shares under option (in shares)	501,086	397,875
Unvested, weighted average grant-date fair value (in dollars per share)	$ 4.17	$ 2.03
Granted, shares under option (in shares)	554,065	425,648
Granted, weighted average grant-date fair value (in dollars per share)	$ 2.97	$ 5.39
Vested, shares under option (in shares)	(286,157)	(322,437)
Vested, weighted average grant-date fair value (in dollars per share)	$ 3.61	$ 3.14
Forfeitures (in shares)	(50,000)	0
Forfeitures (in dollars per share)	$ 2.98	$ 0
Unvested, shares under option (in shares)	718,994	501,086
Unvested, weighted average grant-date fair value (in dollars per share)	$ 3.39	$ 4.17

Note 9 - Stock-based Compensa_7

Note 9 - Stock-based Compensation - Options Outstanding (Details)	12 Months Ended
	Dec. 31, 2021$ / sharesshares
Options outstanding (in shares) | shares	2,463,636
Options outstanding, weighted average remaining contractual life (Year)	7 years 3 months 14 days
Options outstanding, weighted average exercise price (in dollars per share)	$ 5.825
Options exercisable (in shares) | shares	1,744,642
Options excercisable, weighted average remaining contractual life (Year)	6 years 2 months 23 days
Exercise Price Range 1 [Member]
Per share exercise price, lower limit (in dollars per share)	$ 1.10
Per share exercise price, upper limit (in dollars per share)	$ 1.10
Options outstanding (in shares) | shares	14,000
Options outstanding, weighted average remaining contractual life (Year)	1 year 5 months 12 days
Options outstanding, weighted average exercise price (in dollars per share)	$ 1.100
Options exercisable (in shares) | shares	14,000
Options excercisable, weighted average remaining contractual life (Year)	1 year 5 months 12 days
Exercise Price Range 2 [Member]
Per share exercise price, lower limit (in dollars per share)	$ 2.26
Per share exercise price, upper limit (in dollars per share)	$ 2.50
Options outstanding (in shares) | shares	79,225
Options outstanding, weighted average remaining contractual life (Year)	7 years 7 months 13 days
Options outstanding, weighted average exercise price (in dollars per share)	$ 2.310
Options exercisable (in shares) | shares	22,000
Options excercisable, weighted average remaining contractual life (Year)	2 years 5 months 8 days
Exercise Price Range 3 [Member]
Per share exercise price, lower limit (in dollars per share)	$ 2.95
Per share exercise price, upper limit (in dollars per share)	$ 4.17
Options outstanding (in shares) | shares	1,207,940
Options outstanding, weighted average remaining contractual life (Year)	7 years 5 months 12 days
Options outstanding, weighted average exercise price (in dollars per share)	$ 3.410
Options exercisable (in shares) | shares	729,695
Options excercisable, weighted average remaining contractual life (Year)	6 years 18 days
Exercise Price Range 4 [Member]
Per share exercise price, lower limit (in dollars per share)	$ 4.50
Per share exercise price, upper limit (in dollars per share)	$ 8.10
Options outstanding (in shares) | shares	687,100
Options outstanding, weighted average remaining contractual life (Year)	6 years 8 months 8 days
Options outstanding, weighted average exercise price (in dollars per share)	$ 6.134
Options exercisable (in shares) | shares	609,600
Options excercisable, weighted average remaining contractual life (Year)	6 years 5 months 19 days
Exercise Price Range 5 [Member]
Per share exercise price, lower limit (in dollars per share)	$ 9.99
Per share exercise price, upper limit (in dollars per share)	$ 10.10
Options outstanding (in shares) | shares	266,048
Options outstanding, weighted average remaining contractual life (Year)	7 years 11 months 4 days
Options outstanding, weighted average exercise price (in dollars per share)	$ 9.994
Options exercisable (in shares) | shares	160,024
Options excercisable, weighted average remaining contractual life (Year)	7 years 6 months 10 days
Exercise Price Range 6 [Member]
Options outstanding (in shares) | shares	209,323
Options outstanding, weighted average remaining contractual life (Year)	4 years 6 months 25 days
Options outstanding, weighted average exercise price (in dollars per share)	$ 15.10
Options exercisable (in shares) | shares	209,323
Options excercisable, weighted average remaining contractual life (Year)	4 years 6 months 25 days

Note 9 - Stock-based Compensa_8

Note 9 - Stock-based Compensation - Assumptions Used in Calculating Fair Value of Options (Details) - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Expected dividend yield	0.00%	0.00%
Expected stock price volatility	90.00%	90.00%
Minimum [Member]
Common stock fair value (in dollars per share)	$ 2.26	$ 4.82
Risk-free interest rate	0.79%	0.29%
Expected Option life(years) (Year)	5 years 3 months 18 days	5 years
Maximum [Member]
Common stock fair value (in dollars per share)	$ 4.17	$ 9.99
Risk-free interest rate	1.08%	0.39%
Expected Option life(years) (Year)	5 years 9 months	5 years 9 months

Note 9 - Stock-based Compensa_9

Note 9 - Stock-based Compensation - Nonvested Restricted Stock Units Activity (Details) - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Granted, restricted shares (in shares)	21,580
Granted, weighted average grant date fair value (in dollars per share)	$ 4.17
Vested, restricted shares (in shares)	(22,290)
Vested, weighted average grant date fair value (in dollars per share)	$ 3.80
Restricted nonvested (in shares)	10,790
Restricted nonvested, weighted average grant date fair value (in dollars per share)	$ 4.17
Restricted Stock Units (RSUs) [Member]
Restricted nonvested (in shares)	11,500	0
Restricted nonvested, weighted average grant date fair value (in dollars per share)	$ 3.45	$ 0
Granted, restricted shares (in shares)		11,500
Granted, weighted average grant date fair value (in dollars per share)		$ 3.45
Vested, restricted shares (in shares)		0
Vested, weighted average grant date fair value (in dollars per share)		$ 0
Restricted nonvested (in shares)		11,500
Restricted nonvested, weighted average grant date fair value (in dollars per share)		$ 3.45

Note 10 - Income Taxes (Details

Note 10 - Income Taxes (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Taxes Receivable, Current	$ 321,000	$ 323,000
Domestic Tax Authority [Member]
Open Tax Year	2015 2016 2017 2018 2019 2020 2021

Note 10 - Income Taxes - Deferr

Note 10 - Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Net operating loss carryforwards	$ 9,986	$ 7,660
Research credit carryforwards	235	235
Stock-based compensation	1,734	1,498
Other	66	70
Deferred tax assets	12,021	9,463
Valuation allowance	(12,021)	(9,463)
Net deferred tax asset	$ 0	$ 0

Note 10 - Income Taxes - Income

Note 10 - Income Taxes - Income Tax Reconciliation (Details)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Statutory rate	21.00%	21.00%
Permanent differences	2.10%	1.70%
Change in effective tax rate	(0.40%)	0.00%
Valuation allowance	(24.30%)	(26.50%)
Foreign research incentives	3.10%	5.40%
Other	1.60%	3.80%
Effective rate	3.10%	5.40%

Note 10 - Income Taxes - Net Op

Note 10 - Income Taxes - Net Operating Losses and Tax Credit Carryforwards (Details) - Domestic Tax Authority [Member] $ in Thousands	12 Months Ended
	Dec. 31, 2021USD ($)
Net operating losses--federal	$ 12,958
Tax credits--federal	$ 235
Earliest Tax Year [Member]
Net operating losses--federal	2031
Tax credits--federal	2041
Tax Year 2018 [Member]
Net operating losses--federal	$ 12,068

Note 11 - Subsequent Events (De

Note 11 - Subsequent Events (Details Textual) - Subsequent Event [Member] $ in Millions	Feb. 21, 2022USD ($)
Cancer Prevention Pharmaceuticals, Inc. [Member] | Stock and Future Milestone Achievement [Member]
Business Combination, Contingent Consideration, Liability, Total	$ 60
Holders of Panbela [Member]
Percentage of Post-merger Company Ownership	59.00%
Holders of CPP Securities [Member]
Percentage of Post-merger Company Ownership	41.00%